Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00041613 |
Recruitment Status
: Unknown
Verified March 2008 by Introgen Therapeutics.
Recruitment status was: Recruiting
First Posted
: July 12, 2002
Last Update Posted
: April 1, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carcinoma, Squamous Cell | Genetic: INGN 201 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- 18 years or older
- Not eligible for surgery
- Must have had radiation and chemotherapy treatments
- No prior methotrexate treatments

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00041613
Contact: Introgen Therapeutics, Inc. | 866.631.4646 | clinicaltrials@introgen.com | |
Contact: Therapeutics, Inc. |
United States, Colorado | |
Unversity of Colorado Cancer Center | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Brittney Hines 720-848-0678 Brittany.Hines@uchsc.edu | |
Principal Investigator: Madeleine Kane, MD | |
United States, Kentucky | |
Norton Healthcare Pavilion | Recruiting |
Louisville, Kentucky, United States, 40202 | |
Contact: Daniela Neamtu 502-629-4679 daniela.neamtu@nortonhealthcare.org | |
Principal Investigator: John Hamm, MD | |
United States, Maryland | |
Cancer Center of GBMC | Recruiting |
Baltimore, Maryland, United States, 21204 | |
Contact: Lauren Titus 443-849-3285 ltitus@gbmc.org | |
Principal Investigator: Marshall Levine, MD | |
United States, South Carolina | |
WJB Dorn VA Medical Center | Recruiting |
Columbia, South Carolina, United States, 29209 | |
Contact: Justin Reynolds 803-776-4000 ext 6074 justin.reynolds@va.gov | |
Principal Investigator: William Hrushesky, MD | |
United States, Texas | |
Mary Crowley Medical Research Center | Recruiting |
Dallas, Texas, United States, 75201 | |
Contact: Arlen Waclawczyk 214-658-1985 awaclawczyk@mcmrc.com | |
Principal Investigator: John Nemunaitis, MD |
Study Director: | Kerstin Menander, MD | ||
Study Chair: | Julie L Sicam, MT (ASCP) MSHS |
ClinicalTrials.gov Identifier: | NCT00041613 History of Changes |
Obsolete Identifiers: | NCT00040703 |
Other Study ID Numbers: |
T301 |
First Posted: | July 12, 2002 Key Record Dates |
Last Update Posted: | April 1, 2008 |
Last Verified: | March 2008 |
Keywords provided by Introgen Therapeutics:
Refractory Squamous Cell Carcinoma of the Head and Neck |
Additional relevant MeSH terms:
Carcinoma, Squamous Cell Carcinoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell |